A Study to Assess the Cognitive Effects of Fesoterodine in Elderly Subjects

• Status: Completed
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The study is designed to evaluate elements of cognitive function in subjects receiving either fesoterodine or alprazolam.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Pfizer
• Treatments: Alprazolam; Fesoterodine

Criteria

Inclusion Criteria:

• Adult healthy volunteers 65 years and over with minimum MMSE of 26

Exclusion Criteria:

• Prohibited concomitant medications

• Confounding medical conditions

• Clinically significant comorbid diseases

• Hypersensitivity or contraindications to fesoterodine or active control